Navigation Links
Clarient, BioView Initiate Alliance to Finalize Development and Commercialize Non-Invasive Molecular Diagnostic Test for Early Detection of Lung Cancer
Date:12/14/2009

co.il.

About Clarient

Clarient combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by collaborating with the healthcare community to translate cancer research and development into better patient care. Clarient's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine has created the need for a centralized resource which provides leading oncology diagnostic technologies, such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory, which provides the most advanced oncology testing and diagnostic services available. Resulting diagnostic reports and analyses are made available to customers through Clarient's Internet-based portal, PATHSiTE(TM). Clarient also plans to develop and market new, proprietary "companion" diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia/lymphoma. www.clarientinc.com

Forward Looking Statement

Certain statements herein regarding Clarient, Inc. contain forward-looking statements that involve risks and uncertainty. Future events and Clarient's actual results could differ materially from the results reflected in these forward-looking statements. Factors that might cause such a difference include, but are not limited to: Clarient's ability to continue to develop and expand its diagnostic services business, Clarient's ability to expand and maintain a successful sales and marketing organization, Clarient's ability to maintain compliance with financial and other covenants under its credit facilities, limitations on Clarient's ability to borrow funds under its credit facilities based on C
'/>"/>

SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test
2. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
3. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
4. Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients
5. New Research Shows Over-use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist-initiated Physician Intervention
6. Echo Therapeutics Initiates Clinical Study of its New One-Piece Symphony(TM) tCGM Biosensor in Type 1 and Type 2 Diabetic Patients
7. Incept BioSystems Initiates First Human Clinical Trial of its SMART Embryo Culture System for In Vitro Fertilization (IVF)
8. Abbotts XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial
9. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
10. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
11. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014  Neuraltus Pharmaceuticals, Inc. announced ... 2 clinical program of NP001 for the treatment of ... disease) are being highlighted today in an oral presentation ... Group , being held in Bloomington, Minnesota ... hoc  analysis, administration of a high dose of NP001 ...
(Date:9/17/2014)... 17 2014 IBM (NYSE: IBM ) ... IBM technical computing and storage technology to accelerate ... These services deliver critically important information to help ... unique cancer, which could lead to better health ... in general. Today, optimal cancer care ...
(Date:9/17/2014)... , September 17, 2014 ... to congratulate Biocartis commitment in shipping its first ... long-time investor in Biocartis as part of Debiopharm ... fully automated, real-time PCR based molecular diagnostics system, ... access to clinical molecular diagnostic information, anywhere and ...
Breaking Medicine Technology:Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection 2Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection 3Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection 4Debiopharm Diagnostics Portfolio Company Biocartis Ships its First Idylla Instrument 2
... - NanoViricides,Inc. (Pink Sheets: NNVC) discussed today the ... presented along with the,successful BSL3 in vitro studies ... Annual Symposium of the Pan American Society for ... (Pan American Society,for Clinical Virology (PASCV): Clinical Virology ...
... and Symptom Severity; New,Resources for Patients, Parents, WASHINGTON, ... today by the National Consumers League shows that ... days. Four in,ten asthma sufferers understand asthma medication ... recent the diagnosis, the less,knowledgeable adult patients tend ...
Cached Medicine Technology:Global Rabies Treatment May be Possible with NanoViricides Drugs 2New Survey Finds Troubling Data on American Asthma Sufferers 2New Survey Finds Troubling Data on American Asthma Sufferers 3New Survey Finds Troubling Data on American Asthma Sufferers 4New Survey Finds Troubling Data on American Asthma Sufferers 5New Survey Finds Troubling Data on American Asthma Sufferers 6
(Date:9/17/2014)... York (PRWEB) September 17, 2014 The ... increase in worth due to the key driving factors ... advancements. An expected CAGR of 8.2 % puts the ... $730.2 million in 2018, as stated in a Transparency ... Industry Analysis, Size, Share, Growth, Trends, and Forecast 2012 ...
(Date:9/17/2014)... news release is available in Spanish . ... affect more than half of the population in our ... one of which affects liver function. Fat accumulates in ... causes inflammation, fibrosis and finally, cirrhosis. To date, the ... hepatic biopsy. Imaging techniques such as abdominal ecography detect ...
(Date:9/17/2014)... of America (GSA) invites all journalists to attend ... country,s largest interdisciplinary conference in the field of aging ... Media representatives may register free of charge. , An ... gathering at the Walter E. Washington Convention Center and ... "Making Connections: From Cells to Societies" and the program ...
(Date:9/17/2014)... Representatives with Capitol Pain Institute announced ... League Event at the Four Seasons in Austin, Texas. , ... honor to be a sponsor for this great event,” said ... went on to explain that the event, the Torch of ... members at the Four Seasons to honor Torch of Liberty ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Neon Sport ... part in the fitness industry’s most anticipated event, Joe ... NV. Two fans will each take home a Neon ... Neon Sport supplements and gear. Fitmark will hold entries ... Olympia Expo, September 19-20th. , “There’s nothing more ...
Breaking Medicine News(10 mins):Health News:Metrology Services Market to Hit USD 720.3 Million by 2018: Transparency Market Research 2Health News:Metrology Services Market to Hit USD 720.3 Million by 2018: Transparency Market Research 3Health News:Magnetic resonance helps to detect and quantify fat in liver 2Health News:Join GSA in Washington, DC, for the Nation's Premier Aging Conference 2Health News:Capitol Pain Institute Sponsoring an Anti-Defamation League Event & Awards Dinner 2Health News:Electrifying Sports Nutrition Brand, Neon Sport, Pairs with Global Fitness Bag & Luggage Brand, Fitmark Bags, for an Exclusive Giveaway at Olympia Expo, This Weekend 2
... ... Pricing Discount! , ... UK (PRWEB) May 12, 2010 -- Citywide Cleaning Services - a division of Citywide Ventures ... 10% pricing discount on any new cleaning contracts. Also, the Company announced that it will ...
... pattern that predicts the likelihood of relapse in patients ... leukemia has been discovered. Researchers publishing in the open ... consistent pattern in five genes that has the potential ... from more aggressive treatment when first diagnosed with T-cell ...
... ... features allow even more companies to save money through better contract management by reduciing ... ... -- Network Contract Solutions has released new features allowing holding companies to take advantage ...
... allergy even exist, researchers find , TUESDAY, May ... information about the prevalence, diagnosis and treatment of food ... studies. , The articles looked at allergies to cow,s ... which account for more than 50 percent of all ...
... Center announced today that it has received a US$100,000 ... Gates Foundation. The grant will support an innovative ... assistant professor in the Department of Microbiology and Immunology, ... Immune Intervention." Joshi,s project is one of 78 ...
... goal of a secure nationwide health information network (NHIN), a ... evaluating the costs, effort and value of what is sometimes ... which appears in the May/June 2010 issue of Journal ... the initial assessment of that framework by health information exchange ...
Cached Medicine News:Health News:Cleaning Service Pricing Discount 2Health News:Genetic pattern that predicts leukemia relapse discovered 2Health News:Network Contract Solutions Adds Holding Company Features to Extend Market Reach and Client Base 2Health News:Few High-Quality Studies on Food Allergies, Say Reviewers 2Health News:OUHSC receives $100,000 Grand Challenges Explorations grant for innovative global health research 2Health News:Measuring success: Regenstrief helps assess value of investment in health info tech 2
QC 123 is an assayed quality control material for blood gas instrumentation. It is available in three (3) levels for monitoring analyzer performance at varying points within the clinical range....
For the qualitative detection of Wuchereria bancrofti antigen in whole blood, serum and plasma specimens...
For the qualitative detection of Hepatitis B surface Antigen (HBsAG) in human serum, plasma and whole blood specimens...
For the qualitative detection of luteinising Hormone (LH) in urine specimens...
Medicine Products: